MARC REITMAN: Open Payments
NPI 1245395151 · HUNTINGTON, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,106 in 52 payments from 15 companies in 2025. Trend: 2023 $1,414 · 2024 $1,576 · 2025 $1,106
Food & beverage: $1,106
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $160 |
| Neurocrine BioSciences, Inc. | 5 | $138 |
| ABBVIE INC. | 5 | $119 |
| Axsome Therapeutics, Inc. | 5 | $108 |
| Bausch Health US, LLC | 4 | $96 |
| Teva Pharmaceuticals USA, Inc. | 4 | $79 |
| Lundbeck LLC | 3 | $75 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $65 |
| Corium, LLC | 3 | $61 |
| Collegium Pharmaceutical, Inc. | 2 | $49 |
Products named: TRINTELLIX, INGREZZA, VRAYLAR, Auvelity, APLENZIN, REXULTI, AUSTEDO XR, CAPLYTA.
Industry payments across NY — which companies pay providers there.
